Predicting Ultrasound-Guided Thoracic PVB Success in Herpetic Neuralgia

Condition(s) studied

Investigational drug(s) / intervention(s)

Ultrasound-Guided Thoracic Paravertebral nerve block: The patients will receive ultrasound-guided TPVB with 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone (10 mL volume)

Ultrasound-Guided Thoracic Paravertebral nerve block: ultrasound-guided TPVB with 10 mL of saline without knowing which treatment they are receiving, maintaining blinding throughout the study.

Study summary

This study aims to fill the knowledge gap by investigating the predictors of success for TPVB in patients with herpetic neuralgia. By identifying demographic, clinical, previous medications and procedural factors associated with positive outcomes, this research seeks to enhance the efficacy of TPVB and improve pain management strategies for patients suffering from herpetic neuralgia.

Eligibility

Primary outcome measure(s)

• The Numeric Pain Rating Scale (NRS) — baseline , 24 hours , 2 weeks ,6 weeks , 3 months and 6 months post- intervention
  The patient is asked to make three pain ratings, corresponding to current, best and worst pain experienced over the past 24 hours. The average of the 3 ratings was used to represent the patient's level of pain over the previous 24 hours

Trial sites (1)

More Beni-Suef University trials in Egypt

Other trials for the same condition